Pharmacokinetics of Single Doses of BILR 355 BS Given With Ritonavir in Healthy Male Volunteers

NCT02253953 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2014-10-01

No results posted yet for this study

Summary

Assessment of the effect of two times oral 100 mg ritonavir capsules on pharmacokinetics of a single dose of BILR 355 BS dissolved in PEG 400

Conditions

  • Healthy

Interventions

DRUG

BILR 355 BS, D1

DRUG

BILR 355 BS, D2

DRUG

BILR 355 BS, D3

DRUG

BILR 355 BS, D4

DRUG

BILR 355 BS, D5

DRUG

BILR 355 BS, D6

DRUG

BILR 355 BS, D7

DRUG

BILR 355 BS, D8

DRUG

BILR 355 BS, D10

DRUG

Placebo

OTHER

high-fat breakfast

DRUG

Ritonavir

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2003-12-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02253953 on ClinicalTrials.gov